At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 7 enrolled
Drug / intervention
TCAD +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot, Randomized Study Comparing the Safety, Tolerability and Pharmacokinetics of Combination Therapy (Amantadine, Ribavirin, Oseltamivir) Versus Neuraminidase Inhibitor Monotherapy to Influenza Virus Infected Immunocompromised Patients
In Brief
A Phase 2 clinical trial evaluating TCAD, Zanamivir or Oseltamivir, and 1 other intervention for Influenza. Completed, enrolled 7 participants across 2 sites.
Detailed Summary
The purpose of this study is to assess the safety and tolerability of triple combination antiviral drug (TCAD) for use in immunocompromised patients with Influenza A infection, and to gain data on the effectiveness of TCAD
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionAug 2009
Study CompletionJan 2010
TodayJul 2026
First PostedMar 23, 2009
Enrollment StartMar 1, 2009
Primary CompletionAug 1, 2009
Study CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.3 years ago
Interventions
TCADdrug
TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
Zanamivir or Oseltamivirdrug
Zanamivir or Oseltamivir
Open label treatment with TCADother
TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)